Diabetologia:LAGB可降低肥胖患者向T2DM进展风险

2014-01-08 佚名 丁香园

肥胖和糖代谢紊乱是2型糖尿病的主要危险因素。为了确定腹腔镜可调节胃束带术(LAGB)治疗是否可以降低空腹血糖受损(IFG)到糖尿病进展的风险,来自澳大利亚莫纳什大学Paul E. O‘Brien教授及其团队进行了一向研究,该研究发现LAGB可降低肥胖IFG患者向糖尿病进展的风险。该研究结果在线发表在2013年12月07日的Diabetologia杂志上。【原文下载】&nbs

肥胖和糖代谢紊乱是2型糖尿病的主要危险因素。为了确定腹腔镜可调节胃束带术(LAGB)治疗是否可以降低空腹血糖受损(IFG)到糖尿病进展的风险,来自澳大利亚莫纳什大学Paul E. O‘Brien教授及其团队进行了一向研究,该研究发现LAGB可降低肥胖IFG患者向糖尿病进展的风险。该研究结果在线发表在2013年12月07日的Diabetologia杂志上。【原文下载】 

该研究是一项回顾性队列研究,在接受LAGB治疗的IFG肥胖患者中进行。最小随访期不低于4年后,受试者的体重和糖尿病结局与以人群为基础的AusDiab研究中澳大利亚成年IFG患者进行比较。


该研究结果表明,共确定了281例基线有IFG的LAGB患者。受试者的年龄和BMI分别为46±9岁和46±9kg/m2.体重下降最低、中间和最高三分为数患者糖尿病发病率分别为每1000人年19.1、3.4和1.8例。AusDiab队列受试者的BMI较低(28±5kg/m2),而且糖尿病发病率为每1000人年12.5例。分析仅限于322例肥胖AusDiab受试者是,糖尿病发病率增加至每1000人年20.5例,高于LAGB组总的糖尿病发病率(每1000人年8.2例)。合并LAGB和AusDiab数据的多变量分析提示LAGB与糖尿病风险下降75%有关。

该研究发现,在IFG肥胖患者中,LAGB后体重下降与随后4年期间向糖尿病进展风险大幅下降有关。在这个人群中,减肥手术可能是一种有效的糖尿病预防策略。

研究背景:有效预防2型糖尿病策略对处理这种疾病巨大的健康和经济负担是必要的。空腹血糖受损(IFG)和/或糖耐量异常(IGT)患者发生2型糖尿病的风险高,而且肥胖增加IGT向糖尿病进展的风险。在中等肥胖的IGT人群中,强化生活方式干预或二甲双胍、阿卡波糖和吡格列酮等药物治疗可使这些患者向2型糖尿病进展的风险降低30-70%.

原文出处:

Wentworth JM, Hensman T, Playfair J, Laurie C, Ritchie ME, Brown WA, Skinner S, Shaw JE, O'Brien PE.Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes.Diabetologia. 2013 Dec 7.【原文下载】 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759384, encodeId=06ab1e593845a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 07 11:25:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950941, encodeId=3db419509411b, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon Feb 10 13:25:00 CST 2014, time=2014-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636789, encodeId=762e1636e899b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 10 02:25:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759384, encodeId=06ab1e593845a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 07 11:25:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950941, encodeId=3db419509411b, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon Feb 10 13:25:00 CST 2014, time=2014-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636789, encodeId=762e1636e899b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 10 02:25:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759384, encodeId=06ab1e593845a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 07 11:25:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950941, encodeId=3db419509411b, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon Feb 10 13:25:00 CST 2014, time=2014-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636789, encodeId=762e1636e899b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 10 02:25:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]

相关资讯

胃绑带术可缓解糖尿病(APEX研究)

  美国APEX研究(一项为期5年的前瞻性观察性研究)中期分析显示,对于肥胖的2型糖尿病患者,腹腔镜下可调节胃绑带术(LAGB)是一种可行的辅助疗法。该结果公布于第21届美国临床内分泌医师学会(AACE)年会。   APEX研究纳入66例接受LAGB的患者,在术后2年时对其进行中期评估。结果显示,术后糖尿病缓解(撤除所有降糖药)及糖尿病改善(用药减少或血糖控制总体改善)率分别为48.5%和47%